MétaCan
Menu
Back to cohort
Record W2089120390 · doi:10.1001/jama.300.8.954

Single-Patient Rooms for Safe Patient-Centered Hospitals

2008· article· en· W2089120390 on OpenAlexaff
Michael E. Detsky

Bibliographic record

VenueJAMA · 2008
Typearticle
Languageen
FieldMedicine
TopicPharmaceutical Practices and Patient Outcomes
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsMedicineMedical emergencyPatient safetyPatient-centered careMEDLINEEmergency medicineHealth care

Abstract

fetched live from OpenAlex

1. Food and Drug Administration. Developing guidance on conducting scientifically sound pharmacoepidemiologic safety studies using large electronic healthcare data sets: public workshop: request for comments. Fed Regist. 2008;73 (79):21963-21964. 2. Food and Drug Administration. The Sentinel Initiative: national strategy for monitoring medical product safety. http://www.fda.gov/oc/initiatives/advance/reports /report0508.pdf. Accessed July 17, 2008. 3. Misbin RI. Medical office review of Avandia: application number: 021071: Center for Drug Evaluation and Research. http://oversight.house.gov/story.asp?ID= 1325. Accessed July 17, 2008. 4. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427-2443. 5. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096-1105. 6. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) Study: interim findings on cardiovascular hospitalizations and deaths. N Engl J Med. 2007; 357(1):28-38. 7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2472. 8. Vandenbroucke J. Observational research, randomised trials, and two views of medical science. PLoS Med. 2008;5:e67; supplemental material. http://medicine .plosjournals.org/archive/1549-1676/5/3/supinfo/10.1371_journal.pmed.0050067 .sd001.pdf. 9. Joffe HV, Parks M, Meyer R, Jenkins J, Temple R. Rosiglitazone and the FDA. N Engl J Med. 2007;357(17):1775-1776. 10. Psaty BM, Ray W. FDA guidance on off-label promotion and the state of the literature from sponsors. JAMA. 2008;299(16):1949-1951. 11. Food and Drug Administration Amendments Act of 2007. HR 3580, enacted by the House and Senate, Pub L No. 110-85. http://frwebgate.access.gpo.gov /cgi-bin/getdoc.cgi?dbname=110_cong_billsd147(8):573-577. 13. Rossouw JE; Writing Group for the Women’s Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-333. 14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002; 288(23):2998-3007. 15. Gerstein HC; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-2559.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.845
Threshold uncertainty score0.506

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.118
GPT teacher head0.352
Teacher spread0.234 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations57
Published2008
Admission routes1
Has abstractyes

Explore more

Same venueJAMASame topicPharmaceutical Practices and Patient OutcomesFrench-language works237,207